Press release
Sarcopenia Therapeutics - Pipeline Review 2018, Clinical Trials, Results, Designations and Developments
Explore report sample at: https://www.psmarketresearch.com/market-analysis/sarcopenia-therapeutics-pipeline-analysis/report-sample
Novartis AG, and Regeneron Pharmaceuticals Inc., have one drug candidate each in the Phase II stage of development for the treatment of the disease. In December 2017, Biophytis SAS announced that the Federal Agency for Medicines and Health Products (FAMHP) approved to conduct the SARA-INT Phase II interventional study of sarcopenia in Belgium.
It has been observed that most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of sarcopenia. For instance, in June 2016, Novartis AG received patent for the invention related to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of age-related sarcopenia (WO2015IB59369 20151204). Patent approval helps in increasing opportunities for invention improvement and uniqueness for the pharmaceutical companies.
Browse report at: https://www.psmarketresearch.com/market-analysis/sarcopenia-therapeutics-pipeline-analysis
Some of the key players developing drugs for the treatment of sarcopenia include Novartis AG, Biophytis SAS and Vibe Pharmaceuticals LLC.
About P&S Intelligence
P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.
Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sarcopenia Therapeutics - Pipeline Review 2018, Clinical Trials, Results, Designations and Developments here
News-ID: 1233596 • Views: …
More Releases from P&S Intelligence - Pharmaceuticals
Cyclin-Dependent Kinase Inhibitors Therapeutics Key Players Analysis - Merck, El …
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development.
CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation.
Download report sample at: http://bit.ly/2eqiPu5
**Various collaborations for CDK inhibitors drug development
Eli Lilly…
Systemic Lupus Erythematosus Pipeline Analysis - Anthera Pharmaceuticals, Inc., …
The study analyzed that the systemic lupus erythematosus pipeline comprises of 57 drug candidates in different stages of development.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/systemic-lupus-erythematosus-pipeline-analysis/report-sample
Systemic lupus erythematosus is a type of lupus in which the immune system damages its own tissues. The disease affects many parts of the body including skin, joints, lungs, brain, blood vessels and kidneys. The systemic lupus erythematosus is caused by impaired immune system due to which the…
Herpes Simplex Virus Infections Therapeutic - Pipeline Analysis, Clinical Trials …
The study analysed that the Herpes simplex virus infections pipeline comprises of 20 drug candidates in different stages of development.
As per the findings of the research, most of the drug candidates are being developed to be administered by oral route.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/hsv-infections-therapeutics-pipeline-analysis/report-sample
Many technologies are being developed that offer promising innovative treatments which can control the progression of Herpes simplex virus infections. The technologies include, but not limited to,…
Japanese Encephalitis Therapeutics - Pipeline Analysis, Clinical Trials, Patent …
Japanese encephalitis is a viral infection that spreads by mosquito bites. The study analyzed that the Japanese encephalitis therapeutics pipeline comprises approximately 12 drug candidates in different stages of development.
Explore report sample at: https://www.psmarketresearch.com/market-analysis/japanese-encephalitis-therapeutics-pipeline/report-sample
The companies developing drugs for the treatment of Japanese encephalitis are laying more emphasis on the drug candidates to be developed as vaccines, due to the promising results shown by these candidates the in the clinical development.…
More Releases for Novartis
Oncology Drugs Market Competitive Outlook - GlaxoSmithKline, Novartis, Merck
"The oncology drugs market consists of sales of oncology drugs and related services by entities (organizations, sole traders and partnerships) that produce oncology drugs to diagnose and treat all types of cancers. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain tumor, and other cancer types. The pharmaceutical industry develops drugs to…
Rydapt Market 2020 Clinical Analysis – Novartis
Global Rydapt Market Growth 2020-2025
The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Rydapt Market on the basis of stating current situation of the industry in 2020.
This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought…
Gleevec Market Overall Study Report 2020-2027 | Novartis
Gleevec Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the Gleevec market between 2020 and 2027. In terms of value, the Gleevec industry is expected to register a steady CAGR during the forecast period.
The report offers a systematic presentation of the existing trends,…
Rydapt Market Demand & Competitive Analysis by 2025| Novartis
Market Research Report Store offers a latest published report on Rydapt Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth…
Global HER2-negative breast cancer Treatment Market to 2025| AstraZeneca, Bristo …
Researchmoz added Most up-to-date research on "Global HER2-negative breast cancer Treatment Market Size, Status and Forecast 2019-2025" to its huge collection of research reports.
HER2 (human epidermal growth factor receptor 2) is a protein that appears on the surface of some breast cancer cells. It may also be called HER2/neu or ErbB2.HER2-negative breast cancer means that the people have little or no HER2 protein.
In 2018, the global HER2-negative breast cancer Treatment…
Nilotinib Market Report 2018 – 2023: Novartis
The Study Paper in this Global Nilotinib Market includes Novartis.
Get Free Sample Brochure of Nilotinib Market spread across [142 pages] @ https://www.marketgrowthinsight.com/sample/4896
Unbiased perspective on intangible aspects such as key challenges, threats, new entrants as well as strengths and weaknesses of the prominent vendors too are…
